Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

09/13/2021 | 10:08am EST

Item 8.01. Other Events

On September 13, 2021, Y-mAbs Therapeutics, Inc., (the "Company") issued a press release announcing that its partner SciClone Pharmaceuticals (Holdings) Limited has been granted priority review of the Biologics License Application for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma by the Center for Drug Evaluation of China'sNational Medical Products Administration. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 8.01 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits



Exhibit No.   Description

  99.1          Press Release, dated September 13, 2021 issued by Y-mAbs
              Therapeutics, Inc.

104           Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses

All news about Y-MABS THERAPEUTICS, INC.
11/29INSIDER SELL : Y-mAbs Therapeutics
MT
11/24Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
11/24Y-mAbs Therapeutics, Inc. Announces Executive Changes
CI
11/16Y-mAbs Therapeutics Downgraded, Price Target Cut at JPMorgan
MT
11/16JPMorgan Cuts Y-mAbs Therapeutics to Neutral From Overweight, Price Target to $30 From ..
MT
11/04Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments - Fo..
PU
11/04Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q3 Revenue $9M, vs. Street Est of $10.9..
MT
11/04Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
AQ
11/04Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/04Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 66,8 M - -
Net income 2021 -48,8 M - -
Net cash 2021 85,0 M - -
P/E ratio 2021 -15,9x
Yield 2021 -
Capitalization 745 M 745 M -
EV / Sales 2021 9,88x
EV / Sales 2022 3,86x
Nbr of Employees 125
Free-Float 83,8%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 17,08 $
Average target price 46,20 $
Spread / Average Target 170%
EPS Revisions
Managers and Directors
Claus Juan M°ller-San Pedro Chief Executive Officer & Director
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-65.60%743
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.28.27%66 062
VERTEX PHARMACEUTICALS-19.56%48 336